A solid progress update, although it doesn’t contain many surprises. Certainly another de-risked step on the way to Colostat as a marketable product. There’s little trade volume and one has to wonder what it’s going to take to bring the share price back above the ipo of .20. Seems very undervalued considering the milestones that have been achieved. A good result from Study 6 (Q1 2029?) will undoubtably make this company worth a lot of money.
Ann: Final Antibody Selection Complete, page-3
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
